Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma

Table 1

COX2 and PPARG expression analysis of skin tumors using TMA-1.

Tumor entity	Cytoplasmic COX2 immunoreactivity						Nuclear PPARG immunoreactivity						$P^{†}$
	$n$ analyzable	0 ($n$)	1+ ($n$)	2+ ($n$)	3+ ($n$)	$P^{*}$	$n$ analyzable	0 ($n$)	1+ ($n$)	2+ ($n$)	3+ ($n$)	$P^{*}$
TMA-1: total ($n=323$)	186	34	86	54	12		212	143	50	19	0		.0003
Melanocytic lesions
Malignant melanoma	38	0	16	17	5	.02	41	21	8	12	0	.001	.01
Benign nevus	19	4	7	8	0		24	22	2	0	0		1.00
Epithelial tumors
Squamous cell carcinoma	30	3	10	11	6	.07	33	23	7	3	0	.001	.62
Basal cell carcinoma	31	7	16	7	1		33	11	21	1	0		.57
Connective tissue tumors
Kaposi sarcoma	15	6	8	1	0	.61	18	13	5	0	0	.13	1.00
Benign histiocytoma	16	8	7	1	0		22	19	1	2	0		.47
Capillary hemangioma	14	3	9	2	0		18	16	2	0	0		1.00
Appendix tumors
Benign sebaceous adenoma	23	3	13	7	0		23	18	4	1	0		1.00

${}^{*}\text{Fisher}$'s exact test (2-sided); bold face representing significant data. ${}^{†}\text{Fisher}$'s exact test (2-sided); association of COX2 and PPARG IHC within single tumor entities.